UBS Starts BMRN, RDEA, ARIA at Buy, ITMN, ACHN, HGSI, IRWD at Neutral

Article Stock Quotes (7) Comments (0)

An analyst at UBS initiated coverage on a number of stocks in the Biotech & Drug sector Thursday morning:

• BioMarin (Nasdaq: BMRN) with a Buy rating and a $43 price target
  
• Ardea Biosciences (Nasdaq: RDEA) with a Buy rating and a $31 price target
  
• Ariad Pharma (Nasdaq: ARIA) with a Buy rating and a $20 price target
  
• InterMune (Nasdaq: ITMN) with a Neutral rating and a $13.50 price target
  
• Achillion Pharma (Nasdaq: ACHN) with a Neutral rating and a $11 price target
  
• Human Genome Sciences (Nasdaq: HGSI) with a Neutral rating and a $8 price target
  
• Ironwood Pharma (Nasdaq: IRWD) with a Neutral rating and a $14 price target

Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
• Topeka Capital Starts CEVA Inc. (CEVA) at Buy
• Evercore Partners Starts Calix (CALX) at Overweight

Create E-mail Alert Related Categories

New Coverage

Related Entities

UBS

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?